Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06856681Not ApplicableWithdrawn

Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

Role: lead

NCT07041450Recruiting

Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Role: collaborator

NCT06025877Active Not Recruiting

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Role: lead

NCT05477056Completed

Quality Improvement PrecivityAD Clinician Survey (QUIP I)

Role: lead

NCT02494024Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Role: lead

All 5 trials loaded